HUWE1 and cancer: The ablation of the expression of an E3 ligase, HectH9, collaboratively increases the sensitivity of PCa cells to 2-DG [39], which is an inhibitor of metabolism that is currently in Phase II clinical trials for the treatment of advanced cancer.